Table 1 Mutated cancer genes and available targeted therapeutics
Gene | Mutation frequency in this study, n (%) | Actionable mutations, n (%) | Targeted therapy |
|---|---|---|---|
EGFRa | 231 (25) | 202 (22) | EGFR TKIs |
BRAFa | 34 (3.6) | 28 (3.0) | Vemurafenib, dabrafenib |
HER2a | 16 (1.7) | 16 (1.7) | Afatinib, trastuzumab |
KRAS, HRAS, NRAS | 298 (32) | 298 (32) | MEK inhibitors |
CDKN2A | 38 (4.1) | 38 (4.1) | Cell cycle inhibitors |
IDH1, IDH2 | 6 (0.64) | 6 (0.64) | IDH inhibitors |
PIK3CA, PTEN | 55 (5.8) | 55 (5.8) | PI3 kinase inhibitors |
ATM | 39 (4.2) | 39 (4.2) | PARP inhibitors |
STK11 | 26 (2.8) | 26 (2.8) | mTOR inhibitors |